Strides Pharma Scien
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
** Pharmaceutical company Strides Pharma Science's shares SRID.NS rise as much as 10.29%, biggest single-day jump in about seven months, to 1056 rupees apiece; last up 4.7%
** Uptick after SRID says its flagship manufacturing facility in Bengaluru received the Establishment Inspection Report (EIR) from the U.S. drug regulator, indicating successful closure of inspection at the facility
** U.S. Food and Drug Administration (USFDA) had conducted a good manufacturing practices inspection from May 12 to May 20, and issued a Form 483 with five observations
** Current closure of the inspection comes after SRID addressed all the observations by the USFDA within the stipulated timeline
** Stock is most active in seven months, with trading volume of 2584,969 shares as of 11:03 a.m. IST, 10.2x the 30-day average, according to data compiled by LSEG
** SRID shares are up 10.7% in 2026 so far
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463;))
** Pharmaceutical company Strides Pharma Science's shares SRID.NS rise as much as 10.29%, biggest single-day jump in about seven months, to 1056 rupees apiece; last up 4.7%
** Uptick after SRID says its flagship manufacturing facility in Bengaluru received the Establishment Inspection Report (EIR) from the U.S. drug regulator, indicating successful closure of inspection at the facility
** U.S. Food and Drug Administration (USFDA) had conducted a good manufacturing practices inspection from May 12 to May 20, and issued a Form 483 with five observations
** Current closure of the inspection comes after SRID addressed all the observations by the USFDA within the stipulated timeline
** Stock is most active in seven months, with trading volume of 2584,969 shares as of 11:03 a.m. IST, 10.2x the 30-day average, according to data compiled by LSEG
** SRID shares are up 10.7% in 2026 so far
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463;))
Strides Pharma Science received an Establishment Inspection Report from the US Food and Drug Administration for its flagship Bengaluru manufacturing facility, closing a cGMP inspection held from 12 to 20 May 2026 with a Voluntary Action Indicated classification. The inspection had produced five Form 483 observations, and the company submitted responses alongside corrective and preventive actions. The site manufactures tablets, capsules and oral liquids for regulated and other international markets, supporting existing commercial products and future growth opportunities. Strides reported FY26 revenue of ₹48,587 million, with the US contributing 51% of the total.
Powered by Tijori
Strides Pharma Science received an Establishment Inspection Report from the US Food and Drug Administration for its flagship Bengaluru manufacturing facility, closing a cGMP inspection held from 12 to 20 May 2026 with a Voluntary Action Indicated classification. The inspection had produced five Form 483 observations, and the company submitted responses alongside corrective and preventive actions. The site manufactures tablets, capsules and oral liquids for regulated and other international markets, supporting existing commercial products and future growth opportunities. Strides reported FY26 revenue of ₹48,587 million, with the US contributing 51% of the total.
Powered by Tijori
Aug 19 (Reuters) - Strides Pharma Science Ltd SRID.NS:
RECEIVES US FDA ESTABLISHMENT INSPECTION REPORT FOR BENGALURU FACILITY
Further company coverage: SRID.NS
(([email protected];;))
Aug 19 (Reuters) - Strides Pharma Science Ltd SRID.NS:
RECEIVES US FDA ESTABLISHMENT INSPECTION REPORT FOR BENGALURU FACILITY
Further company coverage: SRID.NS
(([email protected];;))
July 31 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE JUNE-QUARTER CONSOL NET PROFIT 1.57 BILLION RUPEES
STRIDES PHARMA SCIENCE JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 12.65 BILLION RUPEES
Source text: ID:nnAZN4TB25V
Further company coverage: SRID.NS
(([email protected];))
July 31 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE JUNE-QUARTER CONSOL NET PROFIT 1.57 BILLION RUPEES
STRIDES PHARMA SCIENCE JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 12.65 BILLION RUPEES
Source text: ID:nnAZN4TB25V
Further company coverage: SRID.NS
(([email protected];))
Strides Pharma Science said on June 27, 2026, that a consortium led by Ascent Capital, along with co‑investor Vintage Classic, will invest in its wholly owned subsidiary Pivot Path Private Limited, a carve‑out from Strides' Global Capability Centre. The transaction values Pivot Path at approximately £2,300 million on a post‑money basis. Strides will realise around £1,000 million while retaining a roughly 20% ownership stake, and the deal includes a primary capital infusion of £500 million to fuel Pivot Path's independent growth. Pivot Path, which was formally separated via an NCLT‑approved Scheme of Arrangement in May 2026, generated revenue of £1,447 million and EBITDA of £169 million in FY26. It offers life sciences consulting, digital transformation, quality and compliance, and AI‑enabled operational services to pharmaceutical clients. Strides' board approved the transaction at a meeting that concluded at 15:50 IST.
Powered by Tijori
Strides Pharma Science said on June 27, 2026, that a consortium led by Ascent Capital, along with co‑investor Vintage Classic, will invest in its wholly owned subsidiary Pivot Path Private Limited, a carve‑out from Strides' Global Capability Centre. The transaction values Pivot Path at approximately £2,300 million on a post‑money basis. Strides will realise around £1,000 million while retaining a roughly 20% ownership stake, and the deal includes a primary capital infusion of £500 million to fuel Pivot Path's independent growth. Pivot Path, which was formally separated via an NCLT‑approved Scheme of Arrangement in May 2026, generated revenue of £1,447 million and EBITDA of £169 million in FY26. It offers life sciences consulting, digital transformation, quality and compliance, and AI‑enabled operational services to pharmaceutical clients. Strides' board approved the transaction at a meeting that concluded at 15:50 IST.
Powered by Tijori
May 18 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE MARCH-QUARTER CONSOL NET PROFIT 1.27 BILLION RUPEES
STRIDES PHARMA SCIENCE MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 13.23 BILLION RUPEES
STRIDES PHARMA SCIENCE LTD - RECOMMENDS FINAL DIVIDEND OF 5 RUPEES PER SHARE FOR FY2026
Source text: ID:nnAZN4SWWQY
Further company coverage: SRID.NS
(([email protected];))
May 18 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE MARCH-QUARTER CONSOL NET PROFIT 1.27 BILLION RUPEES
STRIDES PHARMA SCIENCE MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 13.23 BILLION RUPEES
STRIDES PHARMA SCIENCE LTD - RECOMMENDS FINAL DIVIDEND OF 5 RUPEES PER SHARE FOR FY2026
Source text: ID:nnAZN4SWWQY
Further company coverage: SRID.NS
(([email protected];))
March 17 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - ENTERS AGREEMENT TO BUY AND IN-LICENSE GENERIC BRANDS FROM SANDOZ IN AFRICA
STRIDES PHARMA SCIENCE LTD - INITIAL CONSIDERATION FOR TRANSACTION IS US$ 12 MILLION
STRIDES PHARMA SCIENCE LTD - DEAL EXPECTED TO CLOSE BY END OF Q2 FY27 PENDING REGULATORY APPROVALS
Source text: ID:nBSE8gPcSB
Further company coverage: SRID.NS
(([email protected];))
March 17 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - ENTERS AGREEMENT TO BUY AND IN-LICENSE GENERIC BRANDS FROM SANDOZ IN AFRICA
STRIDES PHARMA SCIENCE LTD - INITIAL CONSIDERATION FOR TRANSACTION IS US$ 12 MILLION
STRIDES PHARMA SCIENCE LTD - DEAL EXPECTED TO CLOSE BY END OF Q2 FY27 PENDING REGULATORY APPROVALS
Source text: ID:nBSE8gPcSB
Further company coverage: SRID.NS
(([email protected];))
Feb 5 (Reuters) - Strides Pharma Science Ltd SRID.NS:
UNIT GETS USFDA EIR REPORT FOR FORMULATIONS FACILITY AT CHESTNUT RIDGE
Further company coverage: SRID.NS
(([email protected];;))
Feb 5 (Reuters) - Strides Pharma Science Ltd SRID.NS:
UNIT GETS USFDA EIR REPORT FOR FORMULATIONS FACILITY AT CHESTNUT RIDGE
Further company coverage: SRID.NS
(([email protected];;))
Jan 30 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - DEC-QUARTER CONSOL NET PROFIT 2.02 BILLION RUPEES
STRIDES PHARMA SCIENCE LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 11.95 BILLION RUPEES
Further company coverage: SRID.NS
(([email protected];))
Jan 30 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - DEC-QUARTER CONSOL NET PROFIT 2.02 BILLION RUPEES
STRIDES PHARMA SCIENCE LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 11.95 BILLION RUPEES
Further company coverage: SRID.NS
(([email protected];))
Oct 31 (Reuters) - Strides Pharma Science Ltd SRID.NS:
SEPT-QUARTER CONSOL NET PROFIT 1.28 BILLION RUPEES
SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 12.21 BILLION RUPEES
Source text: [ID:]
Further company coverage: SRID.NS
(([email protected];;))
Oct 31 (Reuters) - Strides Pharma Science Ltd SRID.NS:
SEPT-QUARTER CONSOL NET PROFIT 1.28 BILLION RUPEES
SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 12.21 BILLION RUPEES
Source text: [ID:]
Further company coverage: SRID.NS
(([email protected];;))
June 16 (Reuters) - Strides Pharma Science Ltd SRID.NS:
UNIT TO DIVEST 100% STAKE IN STRIDES CIS LIMITED
Source text: ID:nBSE8QfTWN
Further company coverage: SRID.NS
(([email protected];;))
June 16 (Reuters) - Strides Pharma Science Ltd SRID.NS:
UNIT TO DIVEST 100% STAKE IN STRIDES CIS LIMITED
Source text: ID:nBSE8QfTWN
Further company coverage: SRID.NS
(([email protected];;))
** Shares of Strides Pharma Science SRID.NS rise 2.4% to 709 rupees
** Co's Q4 consolidated net profit jumps nearly five-fold Y/Y to 856.2 mln rupees ($10 mln), revenue rose ~14%
** SRID says it beat its forecast on all key metrics, including revenue, EBITDA
** Adds, growth led by US business growth, up 21.8% Y/Y and new launches
** Stock up ~5.5% YTD, eyes extending rally for a fourth session
($1 = 85.9340 Indian rupees)
(Reporting by Yagnoseni Das in Bengaluru)
(([email protected];))
** Shares of Strides Pharma Science SRID.NS rise 2.4% to 709 rupees
** Co's Q4 consolidated net profit jumps nearly five-fold Y/Y to 856.2 mln rupees ($10 mln), revenue rose ~14%
** SRID says it beat its forecast on all key metrics, including revenue, EBITDA
** Adds, growth led by US business growth, up 21.8% Y/Y and new launches
** Stock up ~5.5% YTD, eyes extending rally for a fourth session
($1 = 85.9340 Indian rupees)
(Reporting by Yagnoseni Das in Bengaluru)
(([email protected];))
March 19 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE - CO, ARCO LAB APPROVE DEMERGER OF IDENTIFIED BUSINESS OF ARCO LAB
Source text: ID:nNSEbkyWGB
Further company coverage: SRID.NS
(([email protected];))
March 19 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE - CO, ARCO LAB APPROVE DEMERGER OF IDENTIFIED BUSINESS OF ARCO LAB
Source text: ID:nNSEbkyWGB
Further company coverage: SRID.NS
(([email protected];))
March 14 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - UNIT PROPOSED TO ACQUIRE 100% STAKE IN AMEXEL PTE. LTD.
STRIDES PHARMA SCIENCE LTD - UNIT PROPOSES TO CREATE BUSINESS PLATFORM IN SOUTHEAST ASIA
Source text: ID:nBSE5Grkf4
Further company coverage: SRID.NS
(([email protected];))
March 14 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - UNIT PROPOSED TO ACQUIRE 100% STAKE IN AMEXEL PTE. LTD.
STRIDES PHARMA SCIENCE LTD - UNIT PROPOSES TO CREATE BUSINESS PLATFORM IN SOUTHEAST ASIA
Source text: ID:nBSE5Grkf4
Further company coverage: SRID.NS
(([email protected];))
** Shares of Indian Pharma companies which make drugs for HIV rise between 2% to 13%
** U.S. decides to resume funding HIV treatment after pausing the foreign aid on Jan. 26
** Strides Pharma SRID.NS up 13%, Laurus Labs LAUL.NS rise 8%, Aurobindo Pharma ARBN.NS rise 3% and Cipla CIPL.NS up 2%
** Strides, which reported 77% rise in Q3 profit earlier in the day, is top gainer on the pharma index .NIPHARM which is up 1%
** Since Jan. 26, LAUL down 10% and SRID fell 5% as of last close, while SRID was largely flat and Cipla was up 1%
(Reporting by Nishit Navin)
(([email protected];))
** Shares of Indian Pharma companies which make drugs for HIV rise between 2% to 13%
** U.S. decides to resume funding HIV treatment after pausing the foreign aid on Jan. 26
** Strides Pharma SRID.NS up 13%, Laurus Labs LAUL.NS rise 8%, Aurobindo Pharma ARBN.NS rise 3% and Cipla CIPL.NS up 2%
** Strides, which reported 77% rise in Q3 profit earlier in the day, is top gainer on the pharma index .NIPHARM which is up 1%
** Since Jan. 26, LAUL down 10% and SRID fell 5% as of last close, while SRID was largely flat and Cipla was up 1%
(Reporting by Nishit Navin)
(([email protected];))
Jan 20 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - RECEIVES USFDA APPROVAL FOR ACETAMINOPHEN AND IBUPROFEN TABLETS
STRIDES PHARMA SCIENCE LTD - APPROVAL WILL ENHANCE STRIDES' OTC PRODUCT PORTFOLIO
Source text: ID:nBSEbPMJqh
Further company coverage: SRID.NS
(([email protected];;))
Jan 20 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - RECEIVES USFDA APPROVAL FOR ACETAMINOPHEN AND IBUPROFEN TABLETS
STRIDES PHARMA SCIENCE LTD - APPROVAL WILL ENHANCE STRIDES' OTC PRODUCT PORTFOLIO
Source text: ID:nBSEbPMJqh
Further company coverage: SRID.NS
(([email protected];;))
Nov 19 (Reuters) - Strides Pharma Science Ltd SRID.NS:
RECEIPT OF NCLT APPROVAL FOR CREATION OF ONESOURCE
FOLLOWING APPROVAL, ONESOURCE WILL ADVANCE TOWARDS LISTING ITS SHARES
Source text: ID:nNSE69gFWY
Further company coverage: SRID.NS
(([email protected];;))
Nov 19 (Reuters) - Strides Pharma Science Ltd SRID.NS:
RECEIPT OF NCLT APPROVAL FOR CREATION OF ONESOURCE
FOLLOWING APPROVAL, ONESOURCE WILL ADVANCE TOWARDS LISTING ITS SHARES
Source text: ID:nNSE69gFWY
Further company coverage: SRID.NS
(([email protected];;))
Oct 25 (Reuters) - Strides Pharma Science Ltd SRID.NS:
UNIT SPG ACQUIRES REMAINING STAKE IN STRIDES SWITZERLAND FOR CHF 1.01 MILLION
Source text for Eikon: ID:nBSE3YQjWM
Further company coverage: SRID.NS
(([email protected];))
Oct 25 (Reuters) - Strides Pharma Science Ltd SRID.NS:
UNIT SPG ACQUIRES REMAINING STAKE IN STRIDES SWITZERLAND FOR CHF 1.01 MILLION
Source text for Eikon: ID:nBSE3YQjWM
Further company coverage: SRID.NS
(([email protected];))
** Shares of Strides Pharma Science SRID.NS rise 2.5% to 1,599.5 rupees
** The pharma co posted a consolidated net profit of 932.3 mln rupees ($11 mln) vs a loss of 1.31 bln rupees a year ago
** Rev from ops rose 20% Y/Y
** More than 385,000 shares change hands, 1.1x its 30 day avg
** Stock has surged over two-fold so far this year
($1 = 84.0510 Indian rupees)
(Reporting by Ashna Teresa Britto in Bengaluru)
(([email protected] ; ( +91 8078332441))
** Shares of Strides Pharma Science SRID.NS rise 2.5% to 1,599.5 rupees
** The pharma co posted a consolidated net profit of 932.3 mln rupees ($11 mln) vs a loss of 1.31 bln rupees a year ago
** Rev from ops rose 20% Y/Y
** More than 385,000 shares change hands, 1.1x its 30 day avg
** Stock has surged over two-fold so far this year
($1 = 84.0510 Indian rupees)
(Reporting by Ashna Teresa Britto in Bengaluru)
(([email protected] ; ( +91 8078332441))
Oct 16 (Reuters) - Strides Pharma Science Ltd SRID.NS:
ONESOURCE RECEIVES EQUITY COMMITMENTS OF 8.01 BILLION RUPEES
COMMITMENTS FROM MARQUEE INVESTORS AT PRE-MONEY EQUITY VALUATION OF $1.65 BILLION
Source text for Eikon: ID:nBSE7MJ6X7
Further company coverage: SRID.NS
(([email protected];;))
Oct 16 (Reuters) - Strides Pharma Science Ltd SRID.NS:
ONESOURCE RECEIVES EQUITY COMMITMENTS OF 8.01 BILLION RUPEES
COMMITMENTS FROM MARQUEE INVESTORS AT PRE-MONEY EQUITY VALUATION OF $1.65 BILLION
Source text for Eikon: ID:nBSE7MJ6X7
Further company coverage: SRID.NS
(([email protected];;))
Sept 17 (Reuters) - Strides Pharma Science Ltd SRID.NS:
RBI HAS LEVIED COMPOUNDING AMOUNT OF 15.1 MILLION RUPEES ON COMPANY
ORDER IN MATTER OF GRANT OF STOCK OPTONS TO NONRESIDENT EMPLOYEE
Further company coverage: SRID.NS
(([email protected];))
Sept 17 (Reuters) - Strides Pharma Science Ltd SRID.NS:
RBI HAS LEVIED COMPOUNDING AMOUNT OF 15.1 MILLION RUPEES ON COMPANY
ORDER IN MATTER OF GRANT OF STOCK OPTONS TO NONRESIDENT EMPLOYEE
Further company coverage: SRID.NS
(([email protected];))
Sept 16 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - RECEIVES USFDA APPROVAL FOR FLUOXETINE TABS 60 MG
Source text for Eikon: ID:nBSEf6hKM
Further company coverage: SRID.NS
(([email protected];))
Sept 16 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - RECEIVES USFDA APPROVAL FOR FLUOXETINE TABS 60 MG
Source text for Eikon: ID:nBSEf6hKM
Further company coverage: SRID.NS
(([email protected];))
Sept 6 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - GETS USFDA APPROVAL FOR THEOPHYLLINE EXTENDED-RELEASE TABLET
Source text for Eikon: ID:nBSE3w42Yc
Further company coverage: SRID.NS
(([email protected];))
Sept 6 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - GETS USFDA APPROVAL FOR THEOPHYLLINE EXTENDED-RELEASE TABLET
Source text for Eikon: ID:nBSE3w42Yc
Further company coverage: SRID.NS
(([email protected];))
July 29 (Reuters) - Strides Pharma Science Ltd SRID.NS:
INDIA’S STRIDES PHARMA SCIENCE JUNE-QUARTER CONSOL NET PROFIT 702 MILLION
STRIDES PHARMA SCIENCE JUNE-QUARTER CONSOL REVENUE FROM CONTINUING OPERATIONS 10.88 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: SRID.NS
(([email protected];))
July 29 (Reuters) - Strides Pharma Science Ltd SRID.NS:
INDIA’S STRIDES PHARMA SCIENCE JUNE-QUARTER CONSOL NET PROFIT 702 MILLION
STRIDES PHARMA SCIENCE JUNE-QUARTER CONSOL REVENUE FROM CONTINUING OPERATIONS 10.88 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: SRID.NS
(([email protected];))
** Shares of Strides Pharma Science SRID.NS up 7.8% at 911.75 rupees after rising as much as 8.7% earlier
** Pharmaceutical co reports Q4 consolidated net profit at 181.8 mln rupees ($2.2 mln) vs loss of 95.4 mln rupees yr ago
** Rev from ops rose 9.9% Y/Y
** Stock is witnessing its most active trading session since Feb. 14, with more than 1.6 mln shares changing hands, 5.8x of 30-day avg
** Co sees continuing business revenue to grow at 12-15% Y/Y for FY25
** Says its U.S. business revenue to be in $285 mln-$300 mln range for FY25
** Stock rose ~21% in March quarter, its fourth straight quarterly rise
($1 = 83.2502 Indian rupees)
(Reporting by Ashish Chandra in Bengaluru)
(([email protected] (+91 7982114624))
** Shares of Strides Pharma Science SRID.NS up 7.8% at 911.75 rupees after rising as much as 8.7% earlier
** Pharmaceutical co reports Q4 consolidated net profit at 181.8 mln rupees ($2.2 mln) vs loss of 95.4 mln rupees yr ago
** Rev from ops rose 9.9% Y/Y
** Stock is witnessing its most active trading session since Feb. 14, with more than 1.6 mln shares changing hands, 5.8x of 30-day avg
** Co sees continuing business revenue to grow at 12-15% Y/Y for FY25
** Says its U.S. business revenue to be in $285 mln-$300 mln range for FY25
** Stock rose ~21% in March quarter, its fourth straight quarterly rise
($1 = 83.2502 Indian rupees)
(Reporting by Ashish Chandra in Bengaluru)
(([email protected] (+91 7982114624))
May 10 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - STRIDES RECEIVES USFDA APPROVAL FOR SEVELAMER CARBONATE TABLETS, 800 MG
Source text for Eikon: [ID:]
Further company coverage: SRID.NS
(([email protected];))
May 10 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - STRIDES RECEIVES USFDA APPROVAL FOR SEVELAMER CARBONATE TABLETS, 800 MG
Source text for Eikon: [ID:]
Further company coverage: SRID.NS
(([email protected];))
April 9 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES RECEIVES USFDA APPROVAL FOR FLUOXETINE TABS 10 MG AND 20 MG
Source text for Eikon: ID:nBSE6GNL4V
Further company coverage: SRID.NS
(([email protected];))
April 9 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES RECEIVES USFDA APPROVAL FOR FLUOXETINE TABS 10 MG AND 20 MG
Source text for Eikon: ID:nBSE6GNL4V
Further company coverage: SRID.NS
(([email protected];))
March 29 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - PROPOSES TO CONSOLIDATE GROUP'S SOUTH AFRICAN BUSINESS UNDER TRINITY PHARMA (PROPRIETARY) LIMITED, SOUTH AFRICA
Source text for Eikon: ID:nBSE15mLyg
Further company coverage: SRID.NS
(([email protected];;))
March 29 (Reuters) - Strides Pharma Science Ltd SRID.NS:
STRIDES PHARMA SCIENCE LTD - PROPOSES TO CONSOLIDATE GROUP'S SOUTH AFRICAN BUSINESS UNDER TRINITY PHARMA (PROPRIETARY) LIMITED, SOUTH AFRICA
Source text for Eikon: ID:nBSE15mLyg
Further company coverage: SRID.NS
(([email protected];;))
March 28 (Reuters) - Strides Pharma Science Ltd SRID.NS:
CORPORATE INSOLVENCY RESOLUTION PROCESS AGAINST STRIDES ALATHUR STANDS STAYED BY APPELLATE TRIBUNAL
Source text for Eikon: ID:nBSE7qH1Gm
Further company coverage: SRID.NS
(([email protected];))
March 28 (Reuters) - Strides Pharma Science Ltd SRID.NS:
CORPORATE INSOLVENCY RESOLUTION PROCESS AGAINST STRIDES ALATHUR STANDS STAYED BY APPELLATE TRIBUNAL
Source text for Eikon: ID:nBSE7qH1Gm
Further company coverage: SRID.NS
(([email protected];))
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Strides Pharma Scien do?
Strides Pharma Science Limited is a global pharmaceutical company established in 1990, with headquarters in Bangalore, India. It operates in Regulated Markets and Emerging Markets, with a strong R&D facility and presence in 100 countries.
Who are the competitors of Strides Pharma Scien?
Strides Pharma Scien major competitors are Procter&Gamble Healt, Sanofi India, Viyash Scientific, Bliss GVS Pharma, Orchid Pharma, FDC, Guj. Themis Biosyn. Market Cap of Strides Pharma Scien is ₹9,407 Crs. While the median market cap of its peers are ₹6,239 Crs.
Is Strides Pharma Scien financially stable compared to its competitors?
Strides Pharma Scien seems to be less financially stable compared to its competitors. Altman Z score of Strides Pharma Scien is 3.4 and is ranked 8 out of its 8 competitors.
Does Strides Pharma Scien pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Strides Pharma Scien latest dividend payout ratio is 8.29% and 3yr average dividend payout ratio is 4.66%
How has Strides Pharma Scien allocated its funds?
Companies resources are allocated to majorly unproductive assets like Inventory
How strong is Strides Pharma Scien balance sheet?
Balance sheet of Strides Pharma Scien is strong. But short term working capital might become an issue for this company.
Is the profitablity of Strides Pharma Scien improving?
The profit is oscillating. The profit of Strides Pharma Scien is ₹635 Crs for TTM, ₹556 Crs for Mar 2026 and ₹3,593 Crs for Mar 2025.
Is the debt of Strides Pharma Scien increasing or decreasing?
The net debt of Strides Pharma Scien is decreasing. Latest net debt of Strides Pharma Scien is ₹1,260 Crs as of Mar-26. This is less than Mar-25 when it was ₹1,538 Crs.
Is Strides Pharma Scien stock expensive?
Strides Pharma Scien is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Strides Pharma Scien is 15.33, while 3 year average PE is 8.59. Also latest EV/EBITDA of Strides Pharma Scien is 11.59 while 3yr average is 17.54.
Has the share price of Strides Pharma Scien grown faster than its competition?
Strides Pharma Scien has given lower returns compared to its competitors. Strides Pharma Scien has grown at ~0.7% over the last 10yrs while peers have grown at a median rate of 14.25%
Is the promoter bullish about Strides Pharma Scien?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Strides Pharma Scien is 27.91% and last quarter promoter holding is 27.91%.
Are mutual funds buying/selling Strides Pharma Scien?
The mutual fund holding of Strides Pharma Scien is increasing. The current mutual fund holding in Strides Pharma Scien is 8.73% while previous quarter holding is 8.56%.